Monogram Orthopaedics Inc Financials
This page shows Monogram Orthopaedics Inc (MGRM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Monogram’s finances show a development-stage model with equity-financed operations, as cash comes from financing activity rather than revenue, debt, or asset turnover.
FY2024 operating cash flow was-$14.0M , showing cash needs stayed heavy. That came even after R&D spending fell from$10.6M in FY2023 to$8.8M in FY2024, so lower development spend did not materially reduce the funding requirement or improve cash efficiency. The reported cost base is therefore still behaving like a platform under development, not a business that can self-cushion expenses with operating inflows.
The balance sheet looks liquid rather than leveraged: the current ratio improved from 5.2x to 10.6x by FY2024. With total liabilities at only
Cash still rose to
Financial Health Signals
Monogram Orthopaedics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Monogram Orthopaedics Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Monogram Orthopaedics Inc reported a net loss of $16.3M while operations used $14.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Monogram Orthopaedics Inc's EBITDA was -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.7% from the prior year.
Monogram Orthopaedics Inc reported -$16.3M in net income in fiscal year 2024. This represents a decrease of 18.8% from the prior year.
Monogram Orthopaedics Inc earned -$0.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 16.4% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Monogram Orthopaedics Inc held $15.7M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Monogram Orthopaedics Inc's ROE was -112.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 10.0 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Monogram Orthopaedics Inc invested $8.8M in research and development in fiscal year 2024. This represents a decrease of 17.0% from the prior year.
Monogram Orthopaedics Inc spent $200K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
Not reported for fiscal year 2024.
MGRM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.3M0.0% | $2.3M | N/A | $2.2M-8.7% | $2.4M+0.8% | $2.4M | N/A | $2.7M |
| SG&A Expenses | $772K-25.2% | $1.0M | N/A | $1.1M-2.0% | $1.1M+3.0% | $1.1M | N/A | $1.1M |
| Operating Income | -$3.1M+7.9% | -$3.3M | N/A | -$5.1M-41.6% | -$3.6M-0.7% | -$3.6M | N/A | -$3.8M |
| Net Income | -$5.4M-70.7% | -$3.2M | N/A | -$5.0M-42.3% | -$3.5M-0.9% | -$3.5M | N/A | -$996K |
| EPS (Diluted) | -$0.16-60.0% | -$0.10+23.1% | -$0.13+18.8% | -$0.16-45.5% | -$0.110.0% | -$0.11-22.2% | -$0.09-200.0% | -$0.03 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
MGRM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.0M-2.3% | $15.4M-13.6% | $17.8M-12.1% | $20.2M+106.0% | $9.8M-21.7% | $12.5M-24.4% | $16.6M-9.1% | $18.2M |
| Current Assets | $13.5M-2.9% | $13.9M-14.9% | $16.3M-12.6% | $18.6M+129.4% | $8.1M-24.2% | $10.7M-26.8% | $14.6M-9.6% | $16.2M |
| Cash & Equivalents | $12.8M-3.3% | $13.3M-15.3% | $15.7M-5.5% | $16.6M+126.7% | $7.3M-27.5% | $10.1M-25.8% | $13.6M-8.6% | $14.9M |
| Inventory | N/A | N/A | N/A | $290K-2.5% | $298K | N/A | $5K0.0% | $5K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $365K | N/A |
| Total Liabilities | $6.4M+74.0% | $3.7M+12.3% | $3.3M+16.3% | $2.8M+1.2% | $2.8M+19.9% | $2.3M-27.3% | $3.2M-50.0% | $6.4M |
| Current Liabilities | $6.2M+214.9% | $2.0M+28.4% | $1.5M-39.5% | $2.5M+2.8% | $2.5M+25.0% | $2.0M-29.6% | $2.8M-52.7% | $6.0M |
| Total Equity | $8.6M-26.3% | $11.7M-19.4% | $14.5M-16.7% | $17.4M+147.3% | $7.0M-31.1% | $10.2M-23.7% | $13.4M+12.8% | $11.9M |
| Retained Earnings | -$77.0M-7.9% | -$71.4M-5.0% | -$68.0M-6.7% | -$63.7M-8.8% | -$58.6M-6.4% | -$55.0M-6.8% | -$51.5M-7.6% | -$47.9M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
MGRM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M+0.7% | -$2.3M+22.9% | -$3.0M+33.2% | -$4.5M-58.8% | -$2.8M+22.6% | -$3.7M-17.3% | -$3.1M-87.3% | -$1.7M |
| Investing Cash Flow | -$218K-39.7% | -$156K-331.0% | -$36K+1.7% | -$37K | $0+100.0% | -$11K+54.6% | -$24K-622.1% | -$3K |
| Financing Cash Flow | $2.1M+2435.4% | $82K-96.1% | $2.1M-84.5% | $13.8M+24963.9% | $55K-63.6% | $151K-91.8% | $1.9M+432.2% | -$557K |
| Dividends Paid | N/A | N/A | N/A | $121K | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Share Buybacks.
MGRM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -63.1%-35.9pp | -27.3% | N/A | -28.9%+21.3pp | -50.2%-15.9pp | -34.3% | N/A | -8.4% |
| Return on Assets | -36.3%-15.5pp | -20.8% | N/A | -24.9%+11.1pp | -36.0%-8.1pp | -28.0% | N/A | -5.5% |
| Current Ratio | 2.16-4.8x | 7.00-3.6x | 10.57+3.3x | 7.31+4.0x | 3.28-2.1x | 5.40+0.2x | 5.19+2.5x | 2.71 |
| Debt-to-Equity | 0.74+0.4x | 0.31+0.1x | 0.23+0.1x | 0.16-0.2x | 0.39+0.2x | 0.230.0x | 0.24-0.3x | 0.54 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Monogram Orthopaedics Inc Ranks
Frequently Asked Questions
Is Monogram Orthopaedics Inc profitable?
No, Monogram Orthopaedics Inc (MGRM) reported a net income of -$16.3M in fiscal year 2024.
What is Monogram Orthopaedics Inc's EBITDA?
Monogram Orthopaedics Inc (MGRM) had EBITDA of -$14.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Monogram Orthopaedics Inc's return on equity (ROE)?
Monogram Orthopaedics Inc (MGRM) has a return on equity of -112.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Monogram Orthopaedics Inc's operating cash flow?
Monogram Orthopaedics Inc (MGRM) recorded an outflow of $14.0M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Monogram Orthopaedics Inc's total assets?
Monogram Orthopaedics Inc (MGRM) had $17.8M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Monogram Orthopaedics Inc spend on research and development?
Monogram Orthopaedics Inc (MGRM) invested $8.8M in research and development during fiscal year 2024.
What is Monogram Orthopaedics Inc's current ratio?
Monogram Orthopaedics Inc (MGRM) had a current ratio of 10.57 as of fiscal year 2024, which is generally considered healthy.
What is Monogram Orthopaedics Inc's debt-to-equity ratio?
Monogram Orthopaedics Inc (MGRM) had a debt-to-equity ratio of 0.23 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Monogram Orthopaedics Inc's return on assets (ROA)?
Monogram Orthopaedics Inc (MGRM) had a return on assets of -91.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does Monogram Orthopaedics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, Monogram Orthopaedics Inc (MGRM) held $15.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $14.0M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Monogram Orthopaedics Inc's Piotroski F-Score?
Monogram Orthopaedics Inc (MGRM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Monogram Orthopaedics Inc's earnings high quality?
Monogram Orthopaedics Inc (MGRM) reported a net loss of $16.3M while operations used $14.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.